GlassScriptPhysician profile
Chadwick T Caudill
NPI 1871689356
$1,965.14
in general payments reported to CMS, 2019-2025
23 companies · $99.23 in 2025
The $99.23 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $707 · 2020: $267 · 2021: $722 · 2022: $14.55 · 2023: $27.28 · 2024: $129 · 2025: $99.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $255.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $539.58 | 2019-2025 | |
| Avion Pharmaceuticals | $308.56 | 2019-2021 | |
| Allergan, INC. | $292.02 | 2019-2020 | |
| Evofem Biosciences, INC. | $159.26 | 2020-2021 | |
| Astellas Pharma US INC | $86.12 | 2024-2025 | Veozah |
| Organon LLC | $78.97 | 2021-2024 | Nexplanon |
| Lupin INC. | $68.82 | 2019-2020 | |
| Therapeuticsmd, INC. | $55.55 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $51.87 | 2019-2021 | |
| Myovant Sciences INC. | $42.53 | 2021 | |
| Mission Pharmacal Company | $33.29 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $33.23 | 2019 | |
| Mayne Pharma Commercial LLC | $30.16 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.80 | 2019 | |
| Hologic Sales and Service, LLC | $24.78 | 2025 | Thinprep 2000 Processor, Aptima, Third Wave |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $21.34 | 2024 | Slynd |
| Novo Nordisk INC | $18.18 | 2025 | |
| Mylan Pharmaceuticals INC. | $17.93 | 2021 | |
| Agile Therapeutics, INC. | $16.76 | 2021 | |
| Coopersurgical, INC. | $15.00 | 2023 | Paragard T 380a |
| Duchesnay USA Incorporated | $14.80 | 2019 | |
| Sumitomo Pharma America, INC. | $14.07 | 2024 | Gemtesa |
| Daiichi Sankyo INC. | $12.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chadwick Caudill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.